Amgen scores FDA approval for low-platelet treatment

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 9
Volume 17
Issue 9

The Food and Drug Administration (FDA) approved romiplostim (Nplate), the first platelet producer for the treatment of adult chronic ITP (immune thrombocytopenic purpura).

The Food and Drug Administration (FDA) approved romiplostim (Nplate), the first platelet producer for the treatment of adult chronic ITP (immune thrombocytopenic purpura).

 

FDA based its approval on two randomized clinical trials of about 125 patients who had received at least one prior ITP treatment. One study enrolled patients who still had their spleen, the other enrolled patients who did not.

 

During 6 months of treatment, patients who received Nplate had significantly higher platelet counts and maintained those higher counts, compared to those who did not receive the drug. The response to Nplate was higher in those patients who still had their spleen than in those patients who had undergone a splenectomy. In those patients who did not receive Nplate, only one experienced a sustained increase in platelet counts.

 

Amgen’s Nplate is currently not recommended in patients with myelodysplasia. In a study of 44 patients who had myelodysplasia and received Nplate, 4 patients developed leukemia. Further clinical trials in patients with predisposing conditions for leukemia will be needed to determine whether the development of leukemia may relate to the use of Nplate.

 

A Risk Evaluation and Mitigation Strategy (REMS) will be done by FDA to determine if NPlate’s risks outweigh its benefits. The REMS will require that all prescribers and patients enroll in a special program to track the long term safety of Nplate therapy.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content